Status:
COMPLETED
Intestinal Epithelial Fucosylation Affects the Efficacy of Ustekinumab in Crohn's Disease
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University
Conditions:
IBD
Eligibility:
All Genders
18-65 years
Brief Summary
The loss of response rate of ustekinumab(UST) is high, and the specific mechanism has not yet been elucidated. Molecular markers that can accurately predict the efficacy of UST are urgently needed to ...
Eligibility Criteria
Inclusion
- Diagnosed with moderate to severe Crohn's disease
- Receiving treatment with ustekinumab
- Received colonoscopy and collected intestinal tissue samples before and after treatment
Exclusion
- Pregnancy
- Hypersensitivity to any component of ustekinumab
- Cognitive or developmental disabilities prevent you from completing this study
- Combined with diseases such as RA, diabetes, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis and tumors
Key Trial Info
Start Date :
December 26 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06203158
Start Date
December 26 2023
End Date
February 28 2024
Last Update
March 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China, 325000